株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のアスペルギルス症治療薬市場:2019〜2023年

Global Aspergillosis Drugs Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 756754
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.99円で換算しております。
Back to Top
世界のアスペルギルス症治療薬市場:2019〜2023年 Global Aspergillosis Drugs Market 2019-2023
出版日: 2018年12月04日 ページ情報: 英文 110 Pages
概要

世界のアスペルギルス症治療薬市場は2023年までにCAGR4%で拡大すると予測されています。製薬会社によるアスペルギルス症治療薬開発のための連携により、新薬研究開発活動が活発化しています。

当レポートでは、世界のアスペルギルス症治療薬市場について調査し、市場の動向とセグメント別概要、地域別動向、および市場に参入主要企業のプロファイルと競合動向についてまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市況

第4章 市場規模

  • 市場の定義
  • 市場規模
  • 市場規模と予測

第5章 ファイブフォース分析

第6章 製品別市場セグメンテーション

  • セグメンテーション
  • 比較
  • Triazoles
  • その他
  • 市場の機会

第7章 顧客動向

第8章 地域別動向

  • 地域別セグメンテーション
  • 地域別比較
  • 南北アメリカ
  • アジア太平洋地域
  • 欧州・中東・アフリカ
  • 市場の機会

第9章 促進因子と課題

第10章 ベンダー環境

第11章 動向

第12章 ベンダー環境

第13章 ベンダー分析

  • 網羅されるベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Astellas Pharma
  • Gilead
  • Johnson & Johnson Services
  • Merck Sharp & Dohme
  • Pfizer

第14章 付録

図表
  • Exhibit 01: Years in consideration
  • Exhibit 02: Global infectious disease therapeutics market
  • Exhibit 03: Segments of global infectious disease therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Triazoles - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Triazoles - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Other therapeutics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in Americas
  • Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in EMEA
  • Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in APAC
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Decision framework
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Astellas Pharma - Vendor overview
  • Exhibit 47: Astellas Pharma - Business segments
  • Exhibit 48: Astellas Pharma - Organizational developments
  • Exhibit 49: Astellas Pharma - Geographic focus
  • Exhibit 50: Astellas Pharma - Key offerings
  • Exhibit 51: Astellas Pharma - Key customers
  • Exhibit 52: Gilead - Vendor overview
  • Exhibit 53: Gilead - Business segments
  • Exhibit 54: Gilead - Organizational developments
  • Exhibit 55: Gilead - Geographic focus
  • Exhibit 56: Gilead - Key offerings
  • Exhibit 57: Gilead - Key customers
  • Exhibit 58: Johnson & Johnson Services - Vendor overview
  • Exhibit 59: Johnson & Johnson Services - Business segments
  • Exhibit 60: Johnson & Johnson Services - Organizational developments
  • Exhibit 61: Johnson & Johnson Services - Geographic focus
  • Exhibit 62: Johnson & Johnson Services - Segment focus
  • Exhibit 63: Johnson & Johnson Services - Key offerings
  • Exhibit 64: Johnson & Johnson Services - Key customers
  • Exhibit 65: Merck Sharp & Dohme - Vendor overview
  • Exhibit 66: Merck Sharp & Dohme - Business segments
  • Exhibit 67: Merck Sharp & Dohme - Organizational developments
  • Exhibit 68: Merck Sharp & Dohme - Geographic focus
  • Exhibit 69: Merck Sharp & Dohme - Segment focus
  • Exhibit 70: Merck Sharp & Dohme - Key offerings
  • Exhibit 71: Merck Sharp & Dohme - Key customers
  • Exhibit 72: Pfizer - Vendor overview
  • Exhibit 73: Pfizer - Business segments
  • Exhibit 74: Pfizer - Organizational developments
  • Exhibit 75: Pfizer - Geographic focus
  • Exhibit 76: Pfizer - Segment focus
  • Exhibit 77: Pfizer - Key offerings
  • Exhibit 78: Pfizer - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
  • Exhibit 80: List of abbreviations
目次
Product Code: IRTNTR30404

About this market:

Strategic alliances to trend in the market. Pharmaceuticaq companies are working in collaboration for the development of medications for the treatment of aspergillosis. These alliances can enhance R&D activities for new drugs for the management of aspergillosis. Such alliances help companies to develop therapeutic drugs which can be introduced quickly into the market. Technavio's analysts have predicted that the aspergillosis drugs market will register a CAGR of almost 4% by 2023.

Market Overview:

Increasing awareness of aspergillosis

To create awareness about aspergillosis and other diseases and treatment options and avoid delay in diagnosis, the Aspergillus Website, funded by the Fungal Infection Trust in partnership with the University of Manchester, was created. The site provides detailed information about the fungus Aspergillus and the diseases it causes.

Increasing popularity of generic drugs

The development of generic drugs is simple, and less time taking and also requires minimal R&D expenditure than the innovator drugs. Thus, the launch of generic drugs in lesser price than the innovator drugs id diluting and hampering the growth of the aspergillosis drugs market.

For the detailed list of factors that will drive and challenge the growth of the aspergillosis drugs market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Astellas Pharma and Gilead the competitive environment is quite intense. Factors such as the rising strategic alliances and the increasing awareness of aspergillosis, will provide considerable growth opportunities to aspergillosis drugs manufactures. Astellas Pharma, Gilead, Johnson & Johnson Services, Merck Sharp & Dohme, and Pfizer are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Triazoles - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: VENDOR LANDSCAPE

  • Market drivers
  • Market challenges

PART 11: TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Astellas Pharma
  • Gilead
  • Johnson & Johnson Services
  • Merck Sharp & Dohme
  • Pfizer

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
Back to Top